NOTE – IMPORTANT UPDATE TO SHAREHOLDERS: Brodsky & Smith reminds investors of investigations relating to the following companies: Veoneer, Inc. (NYSE – VNE), Acceleron Pharma Inc. (Nasdaq – XLRN), Aspen Technology, Inc. (Nasdaq


BALA CYNWYD, PA / ACCESSWIRE / October 18, 2021 / Brodsky & Smith reminds investors of investigations it is conducting with respect to the following companies for possible fiduciary violations and other federal and state violations in relation to proposed acquisition transactions.If you own shares of any of the stocks listed below and If you wish to discuss the legal consequences of the investigation or if you have any questions, you can contact the law firm of Brodsky & Smith by email or telephone, and they will try to answer your questions without obligation or cost to you. You can contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call the toll free number 855-576-4847. There are no costs or financial obligations for you.

Veoneer, Inc. (NYSE: VNE)

Under the terms of the Merger Agreement, Veoneer will be acquired by Magna International Inc. (“Magna”) (NYSE – MGA) in a cash transaction. Veoneer shareholders will receive only $ 31.25 for each share of Veoneer common stock. The investigation concerns whether Veoneer’s board of directors has violated its shareholder fiduciary duties by failing to conduct a fair trial and whether Magna is paying too little for the company.

For more information, see https://www.brodskysmith.com/cases/veoneer-inc-nyse-vne/, or call 855-576-4847. No cost or obligation for you.

Acceleron Pharma Inc. (Nasdaq: XLRN)

Under the terms of the merger agreement, Acceleron will be acquired by Merck (NYSE – MRK) in a cash transaction with a total capital value of $ 11.5 billion. Acceleron shareholders will receive $ 180.00 in cash for every share of Acceleron they own. The investigation is about whether the Acceleron board of directors has violated its fiduciary duty to shareholders by failing to conduct a fair trial and whether Merck is paying too little for the company.

For more information, see https://www.brodskysmith.com/cases/acceleron-pharma-inc-nasdaq-xlrn/, or call 855-576-4847. No cost or obligation for you.

Aspen Technology, Inc. (Nasdaq: AZPN)

Under the terms of the Merger Agreement, Aspen Technology shareholders will receive $ 87.00 in cash and 0.42 shares of the new AspenTech, a newly incorporated company, per share of Aspen Technology. The investigation concerns whether the Aspen Technology Board has violated its stockholder fiduciary duties by failing to conduct a fair trial and whether Emerson is paying too little for the company.

For more information, see https://www.brodskysmith.com/cases/aspen-technology-inc-nasdaq-azpn/, or call 855-576-4847. No cost or obligation for you.

Brodsky & Smith is a broad-based litigation law firm that represents shareholders in securities and class action lawsuits across the country. Brodsky & Smith attorneys have been appointed as principal class action lawyers by numerous courts across the country and have successfully recovered millions of dollars on behalf of our clients and shareholders. Lawyer advertising. Previous results do not guarantee a similar result.

SOURCE: Brodsky & Smith, LLC

View source version on accesswire.com:
https://www.accesswire.com/668620/NOTICE–IMPORTANT-SHAREHOLDER-INVESTIGATION-UPDATE-Brodsky-Smith-Reminds-Investors-of-Investigations-Related-to-the-Following-Companies-Veoneer-Inc-NYSE –VNE-Acceleron-Pharma-Inc-Nasdaq – XLRN-Aspen-Technology-Inc-Nasdaq – AZPN

About Paige McCarthy

Check Also

Skolem Technologies, a Valour venture portfolio company, raises $20 million in Series A round

Skolem Technologies increased 20 million dollars to enable institutional access to DeFi Investors in Skolem’s …

Leave a Reply

Your email address will not be published.